Therapies for cancer using rlip76

Abstract

The present invention is a composition identified as a region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of the ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells. Medicines may be in the form of antibodies, si-RNA and small molecules that recognize the region.

1 - 30 . (canceled) 
     
     
         31 . A method of inhibiting growth of a malignant cell comprising contacting the malignant cell with an agent effective to inhibit transport activity of RLIP76 in the malignant cell, wherein the malignant cell exhibits an increased expression level of RLIP76 protein relative to a non-malignant cell. 
     
     
         32 . The method of  claim 31 , wherein the agent is an antibody that binds specifically to the RLIP76 protein. 
     
     
         33 . The method of  claim 32 , wherein the antibody binds specifically to an epitope on the RLIP76 protein, wherein the epitope is expressed on the cell surface. 
     
     
         34 . The method of  claim 32 , wherein the antibody binds specifically to a region of RLIP76 consisting essentially of the amino acids of SEQ ID NO:3 or SEQ ID NO:4. 
     
     
         35 . The method of  claim 32 , wherein the antibody is in a composition comprising a pharmaceutically acceptable carrier. 
     
     
         36 . The method of  claim 35 , wherein the composition comprises a liposome. 
     
     
         37 . The method of  claim 31 , wherein the malignant cell is a melanoma cell, a small cell lung carcinoma cell, a non-small cell lung carcinoma cell, an ovarian cancer cell, a prostate cancer cell or an adenocarcinoma cell. 
     
     
         38 . The method of  claim 31 , wherein the malignant cell is a melanoma cell. 
     
     
         39 . The method of  claim 31 , wherein the malignant cell is in a subject. 
     
     
         40 . The method of  claim 31 , wherein the malignant cell is in a human subject. 
     
     
         41 . The method of  claim 31 , wherein the agent is a small molecule antagonist of the RLIP76 transport activity. 
     
     
         42 . A method of inhibiting growth of a malignant cell, wherein the malignant cell exhibits an increased expression level of RLIP76 protein relative to a non-malignant cell, the method comprising contacting the cell with a composition that inhibits expression of RLIP76. 
     
     
         43 . The method of  claim 42 , wherein the composition comprises an anti-sense nucleic acid that is effective to inhibit expression of RLIP76 in the malignant cell. 
     
     
         44 . The method of  claim 43 , wherein the anti-sense nucleic acid is in a composition comprising a pharmaceutically acceptable carrier. 
     
     
         45 . The method of  claim 44 , wherein the composition comprises a liposome. 
     
     
         46 . The method of  claim 44 , wherein the composition comprises a proteoliposome comprising an RLIP76 protein. 
     
     
         47 . The method of  claim 42 , wherein the malignant cell is a melanoma cell, a small cell lung cancer cell, a non-small cell lung cancer cell, an ovarian cancer cell, a prostate cancer cell or an adenocarcinoma cell. 
     
     
         48 . The method of  claim 42 , wherein the malignant cell is a melanoma cell. 
     
     
         49 . The method of  claim 42 , wherein the cell is in a subject. 
     
     
         50 . The method of  claim 42 , wherein the cell is in a human subject. 
     
     
         51 . The method of  claim 42 , wherein the composition comprises a double stranded siRNA molecule that is effective to inhibit expression of RLIP76 in the malignant cell. 
     
     
         52 . A method of inhibiting growth of a malignant cell in a subject, wherein the malignant cell exhibits an increased expression level of RLIP76 protein relative to a non-malignant cell, said method comprising:
 administering to the subject a pharmaceutically acceptable composition comprising an effective amount of an anti-RLIP76 antibody to inhibit RLIP76 transport activity when bound to RLIP76 in a cell.   
     
     
         53 . The method of  claim 52 , wherein the antibody binds specifically to an epitope on the RLIP76 protein, wherein the epitope is expressed on the cell surface. 
     
     
         54 . The method of  claim 52 , wherein the antibody binds specifically to a region of RLIP76 consisting essentially of the amino acids of SEQ ID NO:3 or SEQ ID NO:4. 
     
     
         55 . The method of  claim 52 , wherein the pharmaceutically acceptable composition comprises a liposome. 
     
     
         56 . The method of  claim 52 , wherein the pharmaceutically acceptable composition comprises a proteoliposome comprising an RLIP76 protein. 
     
     
         57 . The method of  claim 52 , wherein the malignant cell is a melanoma cell, a small cell lung carcinoma cell, a non-small cell lung carcinoma cell, an ovarian cancer cell, a prostate cancer cell or an adenocarcinoma cell. 
     
     
         58 . The method of  claim 52 , wherein the malignant cell is a melanoma cell. 
     
     
         59 . A method of inhibiting growth of a malignant cell in a subject comprising:
 administering to the subject a pharmaceutically acceptable composition comprising an effective amount of an anti-sense nucleic acid that is effective to inhibit expression of RLIP76 in the malignant cell.   
     
     
         60 . The method of  claim 59 , wherein the anti-sense nucleic acid is complementary to an mRNA that encodes SEQ ID NO:22. 
     
     
         61 . The method of  claim 59 , wherein the pharmaceutically acceptable composition comprises a liposome. 
     
     
         62 . The method of  claim 59 , wherein the pharmaceutically acceptable composition comprises a proteoliposome comprising an RLIP76 protein. 
     
     
         63 . The method of  claim 59 , wherein the malignant cell is a melanoma cell, a small cell lung cancer cell, a non-small cell lung cancer cell, an ovarian cancer cell, a prostate cancer cell or an adenocarcinoma cell. 
     
     
         64 . The method of  claim 59 , wherein the malignant cell is a melanoma cell.